This study is testing two drugs, IDE196 (Darovasertib) and Crizotinib, for treating a type of eye cancer called metastatic uveal melanoma (MUM). This cancer has spread from the eye to other parts of the body. The study is in Phase 2/3 and is open-label, meaning both doctors and participants know which treatment is being given.

Participants must be HLA-A*02:01 negative, which refers to a specific genetic marker. They must not have had certain types of cancer treatments before. They will be divided into groups to receive either the combination of IDE196 + Crizotinib or other doctor-chosen treatments like pembrolizumab, ipilimumab + nivolumab, or dacarbazine.

The study will explore the right dose of the drug combination and check for safety and how well it works against the cancer. Two doses will be tested at first, and the best one will be chosen for the next part of the study.

• The study lasts for several phases and requires multiple visits.
• Participants may have the option to switch doses based on findings.
• Risks include potential side effects from the drugs tested.